TrialEuropean journal of cancer (Oxford, England : 1990)2022

Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group.

Pooja Hingorani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.